Skip to main content

Medical Swabs Market Size [2022-2028] | to Reach USD 4.59 Billion by 2028, Exhibiting a CAGR of 6.9%

Written by Customer Service on . Posted in Mergers And Acquisitions.

According to the Fortune Business Insights, the Medical Swabs Market size is expected to reach USD 4.59 billion by 2028, exhibiting a CAGR of 6.9%

Pune, India, Jan. 27, 2022 (GLOBE NEWSWIRE) — The global medical swabs market size is expected to reach USD 4.59 billion by 2028, exhibiting a CAGR of 6.9% during the forecast period. The increasing technological innovations in swab production will create lucrative opportunities for this market, states Fortune Business Insights in a report titled, “Medical Swabs Market, 2021-2028.” The market size stood at USD 2.67 billion in 2020 and USD 2.88 billion in 2021.

Notable Development:

April 2021: Mount Sinai Health System introduced Mount Sinai COVID-19 PCR Saliva Testing program to provide quick, noninvasive, and precise testing to support safety for businesses and leisure activities in New York.


Get Sample PDF Brochure: https://www.fortunebusinessinsights.com/enquiry/sample/medical-swabs-market-103318


Surging Demand for Diagnostic Supplies to Augment Growth

A sharp increase in communicable illnesses that culminated in a global pandemic (COVID-19) has led to a surge in demand for diagnostic techniques and supplies. According to Worldo metre statistics, the number of daily new cases in each nation throughout the world has been steadily increasing. In just 24 hours on June 21, 2020, the U.S. registered a total of 16, 142 coronavirus positive cases. As a result of the daily increase in instances, diagnostic tests have increased to give patients with early treatment. Furthermore, in developing nations, there has been an increase in coronavirus infections. For example, as of June 2020, Brazil has a total of more than 12 lakh cases.

However, the shortage in demand-supply may hinder market growth.

Report Scope & Segmentation

Report CoverageDetails
Forecast Period2021 to 2028
Forecast Period 2021 to 2028 CAGR6.9%
2028 Value ProjectionUSD 4.59 Billion
Base Year2020
Market Size in 2020USD 2.88 Billion
Historical Data for2017 to 2019
No. of Pages133
Segments coveredTypes, Application, end-Users and Geography
Growth DriversDemand-Supply Shortage to Limit Market Growth
Rise in Rapid Testing Procedures to Fuel Demand
Increasing Prevalence of Infectious Diseases is Augmenting Growth


To get to know more about the short-term and long-term impact of COVID-19 on this market, Please Visit: https://www.fortunebusinessinsights.com/medical-swabs-market-103318


Competitive Landscape:

Prominent Companies to Accentuate Enormous Market Share
Due to the existence of both major and small-scale industrial players, the market is extremely fragmented. Puritan Medical Products, for example, has a larger market share due to its diverse product range, which includes cotton tipped swabs, polyester swabs, non-woven swabs, and other items. According to the US Food and Drug Administration, the corporation is concentrating on delivering high-quality standard items. Furthermore, the organization has a solid distribution network that helps it increase sales all around the world.


Lists the Key Players in this Market:

  • Puritan Medical Products (Maine, U.S.)
  •  BD (New Jersey, U.S.)
  •  3M (Minnesota, U.S.)
  •  Copan Diagnostics Inc. (Italy, Europe)
  •  FL MEDICAL srl (Italy, Europe)
  •  DLS Medical (U.K., Europe)
  •  Dynarex (New York, U.S.)
  •  Advacare Pharma (Maharashtra, India)


Quick Buy – Medical Swabs Market Research Report:  https://www.fortunebusinessinsights.com/checkout-page/103318


Regional Insights:

Growing Cognizance about Infectious Diseases to Push Growth in North America

In 2020, the North American market was worth USD 1.10 billion. This region’s domination is due to the rising occurrence of infectious illnesses, which necessitates ongoing diagnostic procedures. According to Worldometer figures from September 2021, there were 230 million coronavirus cases globally. As a result, the number of diagnostic procedures performed across the country has increased, as has the need for the product. Due to increased awareness of the necessity for identifying infectious diseases during the pandemic, as well as an increase in research activities for the development of vaccines against the virus, the market in Europe is predicted to rise at a substantial CAGR.


Speak To Our Analyst: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/medical-swabs-market-103318


About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.

Contact Us:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.